Innovation leads the future: the prospect for the treatment of lymphoma from the 56th American Society of Hematology annual meeting

VernacularTitle:创新引领未来:从第56届美国血液学会年会展望淋巴瘤的治疗前景
Author: Yuqin SHONG
Publication Type:Journal Article
Keywords: Lymphoma; Molecular targeted therapy; Cellular immunotherapy; American Society of Hematology annual meeting
From: Journal of Leukemia & Lymphoma 2015;24(3):135-137
CountryChina
Language:Chinese
Abstract: The annually American Society of Hematology (ASH) annual meeting is the biggest feast in this area.The 56th ASH annual meeting showed many important data related with lymphoma.Applied brentuximab vedotin as maintenance therapy after autologous stem cell transplantion,Hodgkin lymphoma (HL) patients acquired significant prolonged progression free survival (PFS).A phase Ⅰ study demonstrated that PD-1 inhibitor,nivolumab,has a high response in heavily treated HL,with ORR 87 ％,which has acquired the approval from FDA.BTK inhibitor,PI3K inhibitor,new CD20 antibodies,bcl-2 inhibitor and lenalidomide all are effective in relapsed or refractory chronic lympholytic leukemia (CLL) and non-Hodgkin' s lymphoma (NHL),but how to apply these new targeted drugs appropriately and combined with current chemotherapy regimens are quite difficult.CAR-T cells targeting CD19,CD20,CD30 or CD138 positive lymphomas are a kind of new cellular therapy,which has showed excellent efficacy.